NCT02280265View on ClinicalTrials.gov

Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A

NAUnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Hemophilia A
Interventions
DRUG

Recombinant Human Coagulation Factor VIII for injection

Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.

Sponsors
All Listed Sponsors
lead

Nanjing Medical University

OTHER